9330EGP
- Active ingredient
- decitabine
- Strength
- 50 mg
- Form
- vial
- Manufacturer
- janssen cilag > sofico pharm
- Route
- injection
Uses
Treatment of adult patients with myelodysplastic syndromes including several risk categories and subtypes.
Do not use if
No specific absolute contraindications listed.
Side effects
Neutropenia, thrombocytopenia, anemia, fever, and infections are common.
Warnings
May cause severe myelosuppression and fetal harm. Regular blood count monitoring is required.
How it works
A nucleoside metabolic inhibitor that reduces DNA methylation and promotes cellular differentiation or apoptosis.
Storage
Store at 20–25°C.